Study groups

  • RSMMM Study Group for Antifungals
    Projects
    • PHARMACOLOGICAL EVALUATION OF A NEW TRIAZOLE DERIVATIVE WITH ANTIFUNGAL ACTIVITY: MXP-4509
    • EVALUATION OF THE SUSCEPTIBILITY PROFILE TO NEWLY MARKETED DRUGS OF FUNGAL STRAINS ISOLATED FROM BLOODSTREAM INFECTIONS IN A MULTICENTRE STUDY IN ROMANIA
    Results:
    • Mareş M, Năstasă V, Moraru R, Doroftei B, Ștefanache A – Comparative in vitro activities of fluconazole, voriconazole, and MXP-4509 against Romanian blood yeast isolates. Mycopathologia 2011, 172, 487-492.
    • Marangoci N, Mareș M, Silion M, Fifere A, Varganici C, Nicolescu A, Deleanu C, Coroabă A, Pinteală M, Simionescu BC. Inclusion complex of a new propiconazole derivative with beta-cyclodextrin: NMR, ESI-MS and preliminary pharmacologcal studies; Results in Pharma Sciences 2011, 1, 27-37.
  • RSMMM Study Group for Fungemia
    Projects
    • ROMANIAN FUNGEMIA SURVEILLANCE STUDY
    Results:
    • B. Minea, V. Năstasă, R. F. Moraru, A. Kolecka, M. M. Flonta, I. Marincu, A. Man, F. Toma, M. Lupșe, B. Doroftei, N. Marangoci, M. Pinteală, T. Boekhout, M. Mareș – Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study. European Journal of Clinical Microbiology and Infectious Diseases 2015; 34:367-383. ISSN 0934-9723.
  • RSMMM Study Group for Aspergillus
    Projects
    • SURVEILLANCE OF AZOLE RESISTANCE IN ASPERGILLUS FUMIGATUS

     

    Results: